Volume 132, Issue 3 | Breast Cancer Research and Treatment

Search all Breast Cancer Research and Treatment articles

Volume 132, Issue 3

April 2012

Special Issue: Translational goals of neoadjuvant therapy

Issue Editors:

Stefan Glück,
Debu Tripathy,
Gunter Minckwitz

42 articles in this issue

Introduction to special issue Translational goals of neoadjuvant therapy
Stefan Glück
Editorial 22 March 2012 Pages: 773 - 773
Using neoadjuvant therapy for breast cancer in clinical practice: when and how?
Debu Tripathy
Editorial 22 March 2012 Pages: 775 - 777
Pathologic complete response after neoadjuvant therapy of breast cancer: pitfalls and shortcomings
Gunter von Minckwitz
Editorial 31 March 2012 Pages: 779 - 780
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
Stefan Glück
Jeffrey S. Ross
Lin Wu
Preclinical Study 04 March 2011 Pages: 781 - 791
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
Makiko Ono
Hitoshi Tsuda
Yasuhiro Fujiwara
Clinical Trial 12 May 2011 Pages: 793 - 805
SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy
Elaina S. R. Collie-Duguid
Kathleen Sweeney
Steven D. Heys
Clinical Trial 22 June 2011 Pages: 807 - 818
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer
Frederik Marmé
Wiebke Werft
Andreas Schneeweiss
Clinical Trial 30 September 2011 Pages: 819 - 831
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
Virginia G. Kaklamani
Kalliopi Siziopikou
William Gradishar
Clinical Trial 27 February 2011 Pages: 833 - 842
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)
Milvia Zambetti
Mauro Mansutti
Gianni Luca
Clinical Trial 13 July 2011 Pages: 843 - 851
The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial
Mohammad Mohammadianpanah
Yaghoub Ashouri
Mohammad Amin Mosleh-Shirazi
Clinical Trial 16 October 2011 Pages: 853 - 861
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)
Gunter von Minckwitz
Silvia Darb-Esfahani
Carsten Denkert
Clinical Trial 12 June 2011 Pages: 863 - 870
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
Cheryl Lin
Meredith Becker Buxton
I-SPY TRIAL Investigators
Epidemiology 28 July 2011 Pages: 871 - 879
A plea for the biopsy marker: how, why and why not clipping after breast biopsy?
Isabelle Thomassin-Naggara
Lucie Lalonde
Isabelle Trop
Review 01 November 2011 Pages: 881 - 893
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
Elisabeth Luporsi
Fabrice André
Jean-Pierre Bellocq
Review Open access 03 November 2011 Pages: 895 - 915
Biopsy sampling of breast lesions: comparison of core needle- and vacuum-assisted breast biopsies
Maribel D. Lacambra
Christopher C. Lam
Gary M. Tse
Preclinical study 23 June 2011 Pages: 917 - 923
Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer
Zsuzsanna Varga
Raymond R. Tubbs
Christian Öhlschlegel
Preclinical Study 23 June 2011 Pages: 925 - 935
Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer
Pawel Domagala
Dominika Wokolorczyk
Wenancjusz Domagala
Preclinical Study 24 June 2011 Pages: 937 - 945
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide
Masatsugu Okishiro
Seung Jin Kim
Shinzaburo Noguchi
Preclinical Study 25 June 2011 Pages: 947 - 953
NQO1 expression correlates inversely with NFκB activation in human breast cancer
Maral Jamshidi
Jirina Bartkova
Heli Nevanlinna
Preclinical Study 25 June 2011 Pages: 955 - 968
Comparative gene expression analysis in mouse models for identifying critical pathways in mammary gland development
Hongbo Zhao
Mini Huang
Yuchun Pan
Preclinical Study 07 July 2011 Pages: 969 - 977
Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes
Mireia Menéndez
Joan Castellsagué
Conxi Lázaro
Preclinical study 07 July 2011 Pages: 979 - 992
A gene transcription signature of obesity in breast cancer
Chad J. Creighton
Yvonne H. Sada
Jenny C. Chang
Preclinical study 13 July 2011 Pages: 993 - 1000
Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2
Xinrong Ma
Namita Kundu
Amy M. Fulton
Preclinical Study 15 July 2011 Pages: 1001 - 1008
Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members
Mads Thomassen
Ana Blanco
Ana Vega
Preclinical study 19 July 2011 Pages: 1009 - 1023
RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data
Balázs Győrffy
Zsombor Benke
Reinhold Schäfer
Preclinical study 16 July 2011 Pages: 1025 - 1034
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents
Gais Kadra
Pascal Finetti
Anthony Gonçalves
Preclinical study 27 July 2011 Pages: 1035 - 1047
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Laura J. Esserman
Donald A. Berry
The I-SPY 1 TRIAL Investigators
Clinical trial Open access 25 December 2011 Pages: 1049 - 1062
Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
B. Ramaswamy
W. Fiskus
J. A. Sparano
Clinical trial 27 December 2011 Pages: 1063 - 1072
Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study
L. Schwentner
R. Wolters
A. Wöckel
Clinical Trial 29 December 2011 Pages: 1073 - 1080
Primary and secondary angiosarcomas of the breast: a single institution experience
Conceição Fraga-Guedes
Helenice Gobbi
Giuseppe Viale
Clinical Trial 30 December 2011 Pages: 1081 - 1088
US follow-up protocol in concordant benign result after US-guided 14-gauge core needle breast biopsy
Ji Hyun Youk
Inkyung Jung
Jin Young Kwak
Clinical trial 05 January 2012 Pages: 1089 - 1097
Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy
Vincent Koppelmans
Michiel B. de Ruiter
Sanne B. Schagen
Epidemiology 29 December 2011 Pages: 1099 - 1106
Clinical and biomarker predictors of side effects from tamoxifen
Wendy Lorizio
Alan H. B. Wu
Elad Ziv
Epidemiology 30 December 2011 Pages: 1107 - 1118
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers
Yael Laitman
Karoline B. Kuchenbaecker
Eitan Friedman
Epidemiology 03 January 2012 Pages: 1119 - 1126
Fruit and vegetables consumption and breast cancer risk: the EPIC Italy study
Giovanna Masala
Melania Assedi
Domenico Palli
Epidemiology 04 January 2012 Pages: 1127 - 1136
Obstetric history and mammographic density: a population-based cross-sectional study in Spain (DDM-Spain)
Virginia Lope
Beatriz Pérez-Gómez
DDM-Spain
Epidemiology Open access 04 January 2012 Pages: 1137 - 1146
Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case–control study
Li-E Wang
Chan H. Han
Qingyi Wei
Epidemiology 05 January 2012 Pages: 1147 - 1155
A dietary pattern derived to correlate with estrogens and risk of postmenopausal breast cancer
Teresa T. Fung
Matthias B. Schulze
Michelle D. Holmes
Epidemiology 06 January 2012 Pages: 1157 - 1162
Mammographic density, parity and age at first birth, and risk of breast cancer: an analysis of four case–control studies
Christy G. Woolcott
Karin Koga
Gertraud Maskarinec
Epidemiology 06 January 2012 Pages: 1163 - 1171
Ipsilateral hemodialysis access after axillary dissection for breast cancer
Oded Olsha
Ilya Goldin
David Shemesh
Brief Report 24 January 2012 Pages: 1173 - 1176
Why do women accept to undergo a nipple sparing mastectomy or to reconstruct the nipple areola complex when nipple sparing mastectomy is not possible?
F. Didier
P. Arnaboldi
J. Y. Petit
Brief Report 19 February 2012 Pages: 1177 - 1184
Lack of caveolin-1 (P132L) somatic mutations in breast cancer
Roberta Ferraldeschi
Ayse Latif
William G. Newman
Letter to the Editor 07 February 2012 Pages: 1185 - 1186